Share-based Payment Arrangement, Expense of CYTOKINETICS INC from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CYTOKINETICS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • CYTOKINETICS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $30,696,000, a 21% increase year-over-year.
  • CYTOKINETICS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $108,030,000, a 19% increase year-over-year.
  • CYTOKINETICS INC annual Share-based Payment Arrangement, Expense for 2024 was $97,840,000, a 36% increase from 2023.
  • CYTOKINETICS INC annual Share-based Payment Arrangement, Expense for 2023 was $72,065,000, a 51% increase from 2022.
  • CYTOKINETICS INC annual Share-based Payment Arrangement, Expense for 2022 was $47,853,000, a 78% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CYTOKINETICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $108,030,000 $30,696,000 +$5,340,000 +21% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $102,690,000 $27,535,000 +$2,913,000 +12% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $99,777,000 $23,549,000 +$1,937,000 +9% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $97,840,000 $26,250,000 +$6,769,000 +35% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $91,071,000 $25,356,000 +$6,640,000 +35% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $84,431,000 $24,622,000 +$5,954,000 +32% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $78,477,000 $21,612,000 +$6,412,000 +42% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $72,065,000 $19,481,000 +$6,028,000 +45% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $66,037,000 $18,716,000 +$5,516,000 +42% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $60,521,000 $18,668,000 +$6,468,000 +53% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $54,053,000 $15,200,000 +$6,200,000 +69% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $47,853,000 $13,453,000 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $13,200,000 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $12,200,000 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $9,000,000 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2017 $9,028,000 $2,528,000 +$682,000 +37% 01 Oct 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 $8,346,000 $2,400,000 +$500,000 +26% 01 Jul 2017 30 Sep 2017 10-Q 03 Nov 2017 2017 Q3
Q2 2017 $7,846,000 $2,200,000 +$400,000 +22% 01 Apr 2017 30 Jun 2017 10-Q 04 Aug 2017 2017 Q2
Q1 2017 $7,446,000 $1,900,000 +$300,000 +19% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2017 2017 Q1
Q4 2016 $7,146,000 $1,846,000 +$479,000 +35% 01 Oct 2016 31 Dec 2016 10-K 05 Mar 2018 2017 FY
Q3 2016 $6,667,000 $1,900,000 +$800,000 +73% 01 Jul 2016 30 Sep 2016 10-Q 03 Nov 2017 2017 Q3
Q2 2016 $5,867,000 $1,800,000 +$600,000 +50% 01 Apr 2016 30 Jun 2016 10-Q 04 Aug 2017 2017 Q2
Q1 2016 $1,600,000 +$700,000 +78% 01 Mar 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q1 2016 $5,267,000 $1,600,000 +$700,000 +78% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2016 2016 Q1
Q4 2015 $4,567,000 $1,367,000 +$537,000 +65% 01 Oct 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
Q3 2015 $4,030,000 $1,100,000 +$200,000 +22% 01 Jul 2015 30 Sep 2015 10-Q/A 15 Dec 2016 2016 Q3
Q2 2015 $3,830,000 $1,200,000 +$300,000 +33% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $3,530,000 $900,000 +$200,000 +29% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $3,330,000 $830,000 01 Oct 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
Q3 2014 $900,000 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2015 2015 Q3
Q2 2014 $900,000 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q1 2014 $700,000 01 Jan 2014 31 Mar 2014 10-Q 04 May 2015 2015 Q1

CYTOKINETICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $97,840,000 +$25,775,000 +36% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $72,065,000 +$24,212,000 +51% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $47,853,000 +$21,021,000 +78% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $26,832,000 +$9,212,000 +52% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $17,620,000 +$6,861,000 +64% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $10,759,000 +$998,000 +10% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
2018 $9,761,000 +$733,000 +8.1% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $9,028,000 +$1,882,000 +26% 01 Jan 2017 31 Dec 2017 10-K 07 Mar 2019 2018 FY
2016 $7,146,000 +$2,579,000 +56% 01 Jan 2016 31 Dec 2016 10-K 05 Mar 2018 2017 FY
2015 $4,567,000 +$1,237,000 +37% 01 Jan 2015 31 Dec 2015 10-K 05 Mar 2018 2017 FY
2014 $3,330,000 -$267,000 -7.4% 01 Jan 2014 31 Dec 2014 10-K 06 Mar 2017 2016 FY
2013 $3,597,000 -$186,000 -4.9% 01 Jan 2013 31 Dec 2013 10-K 03 Mar 2016 2015 FY
2012 $3,783,000 +$714,000 +23% 01 Jan 2012 31 Dec 2012 10-K 06 Mar 2015 2014 FY
2011 $3,069,000 -$948,000 -24% 01 Jan 2011 31 Dec 2011 10-K 07 Mar 2014 2013 FY
2010 $4,017,000 01 Jan 2010 31 Dec 2010 10-K 15 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.